Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lemaitre Vascular (LMAT) Other Operating Expenses (2016 - 2025)

Lemaitre Vascular (LMAT) has disclosed Other Operating Expenses for 16 consecutive years, with $13.4 million as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses rose 6.4% to $13.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $54.5 million through Dec 2025, up 16.53% year-over-year, with the annual reading at $54.5 million for FY2025, 16.53% up from the prior year.
  • Other Operating Expenses for Q4 2025 was $13.4 million at Lemaitre Vascular, up from $11.9 million in the prior quarter.
  • The five-year high for Other Operating Expenses was $14.9 million in Q2 2025, with the low at $2.6 million in Q1 2021.
  • Average Other Operating Expenses over 5 years is $10.5 million, with a median of $11.1 million recorded in 2023.
  • The sharpest move saw Other Operating Expenses plummeted 66.96% in 2021, then surged 199.05% in 2022.
  • Over 5 years, Other Operating Expenses stood at $6.8 million in 2021, then grew by 26.41% to $8.6 million in 2022, then grew by 19.4% to $10.3 million in 2023, then grew by 22.96% to $12.6 million in 2024, then increased by 6.4% to $13.4 million in 2025.
  • According to Business Quant data, Other Operating Expenses over the past three periods came in at $13.4 million, $11.9 million, and $14.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.